nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2D6—Hydroxyurea—psoriasis	0.0661	0.119	CbGbCtD
Atomoxetine—CYP2C19—Cholecalciferol—psoriasis	0.0527	0.095	CbGbCtD
Atomoxetine—CYP3A4—Calcitriol—psoriasis	0.0495	0.0891	CbGbCtD
Atomoxetine—CYP2D6—Cholecalciferol—psoriasis	0.0401	0.0722	CbGbCtD
Atomoxetine—CYP3A4—Methoxsalen—psoriasis	0.0385	0.0693	CbGbCtD
Atomoxetine—CYP2C19—Prednisone—psoriasis	0.0365	0.0658	CbGbCtD
Atomoxetine—CYP2C19—Cyclosporine—psoriasis	0.0346	0.0624	CbGbCtD
Atomoxetine—CYP2D6—Cyclosporine—psoriasis	0.0263	0.0474	CbGbCtD
Atomoxetine—CYP3A4—Cholecalciferol—psoriasis	0.0255	0.0459	CbGbCtD
Atomoxetine—CYP2C19—Dexamethasone—psoriasis	0.0228	0.0411	CbGbCtD
Atomoxetine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0221	0.0398	CbGbCtD
Atomoxetine—CYP3A4—Triamcinolone—psoriasis	0.0221	0.0398	CbGbCtD
Atomoxetine—CYP3A4—Betamethasone—psoriasis	0.019	0.0342	CbGbCtD
Atomoxetine—CYP3A4—Prednisolone—psoriasis	0.0187	0.0337	CbGbCtD
Atomoxetine—CYP3A4—Hydrocortisone—psoriasis	0.0177	0.0319	CbGbCtD
Atomoxetine—CYP3A4—Prednisone—psoriasis	0.0177	0.0318	CbGbCtD
Atomoxetine—CYP2D6—Dexamethasone—psoriasis	0.0173	0.0312	CbGbCtD
Atomoxetine—CYP3A4—Cyclosporine—psoriasis	0.0167	0.0302	CbGbCtD
Atomoxetine—CYP3A4—Dexamethasone—psoriasis	0.011	0.0199	CbGbCtD
Atomoxetine—Ketoprofen—CXCL8—psoriasis	0.000461	0.569	CrCbGaD
Atomoxetine—Pseudoephedrine—TNF—psoriasis	0.000349	0.431	CrCbGaD
Atomoxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000271	0.00875	CbGpPWpGaD
Atomoxetine—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000245	0.0079	CbGpPWpGaD
Atomoxetine—Dry mouth—Triamcinolone—psoriasis	0.000243	0.000589	CcSEcCtD
Atomoxetine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000242	0.000585	CcSEcCtD
Atomoxetine—Anorexia—Hydrocortisone—psoriasis	0.000242	0.000585	CcSEcCtD
Atomoxetine—Diarrhoea—Mycophenolic acid—psoriasis	0.000241	0.000584	CcSEcCtD
Atomoxetine—Angiopathy—Prednisone—psoriasis	0.000241	0.000583	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—psoriasis	0.00024	0.000581	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00024	0.000581	CcSEcCtD
Atomoxetine—Vertigo—Betamethasone—psoriasis	0.000238	0.000577	CcSEcCtD
Atomoxetine—Vertigo—Dexamethasone—psoriasis	0.000238	0.000577	CcSEcCtD
Atomoxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000238	0.00769	CbGpPWpGaD
Atomoxetine—Syncope—Betamethasone—psoriasis	0.000238	0.000576	CcSEcCtD
Atomoxetine—Syncope—Dexamethasone—psoriasis	0.000238	0.000576	CcSEcCtD
Atomoxetine—Pain—Mycophenolate mofetil—psoriasis	0.000238	0.000576	CcSEcCtD
Atomoxetine—Constipation—Mycophenolate mofetil—psoriasis	0.000238	0.000576	CcSEcCtD
Atomoxetine—Infection—Triamcinolone—psoriasis	0.000237	0.000574	CcSEcCtD
Atomoxetine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000235	0.00759	CbGpPWpGaD
Atomoxetine—Feeling abnormal—Cyclosporine—psoriasis	0.000235	0.000569	CcSEcCtD
Atomoxetine—Shock—Triamcinolone—psoriasis	0.000235	0.000568	CcSEcCtD
Atomoxetine—Insomnia—Prednisolone—psoriasis	0.000235	0.000568	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000233	0.000564	CcSEcCtD
Atomoxetine—Loss of consciousness—Dexamethasone—psoriasis	0.000233	0.000564	CcSEcCtD
Atomoxetine—Loss of consciousness—Betamethasone—psoriasis	0.000233	0.000564	CcSEcCtD
Atomoxetine—Dizziness—Mycophenolic acid—psoriasis	0.000233	0.000564	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisolone—psoriasis	0.000233	0.000564	CcSEcCtD
Atomoxetine—Tachycardia—Triamcinolone—psoriasis	0.000233	0.000564	CcSEcCtD
Atomoxetine—Mental disorder—Prednisone—psoriasis	0.000233	0.000563	CcSEcCtD
Atomoxetine—Malnutrition—Prednisone—psoriasis	0.000231	0.000559	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000231	0.000559	CcSEcCtD
Atomoxetine—Hyperhidrosis—Triamcinolone—psoriasis	0.000231	0.000558	CcSEcCtD
Atomoxetine—Convulsion—Betamethasone—psoriasis	0.00023	0.000556	CcSEcCtD
Atomoxetine—Convulsion—Dexamethasone—psoriasis	0.00023	0.000556	CcSEcCtD
Atomoxetine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000229	0.000555	CcSEcCtD
Atomoxetine—Insomnia—Hydrocortisone—psoriasis	0.000229	0.000555	CcSEcCtD
Atomoxetine—Paraesthesia—Hydrocortisone—psoriasis	0.000228	0.000551	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000228	0.00055	CcSEcCtD
Atomoxetine—Urticaria—Cyclosporine—psoriasis	0.000227	0.000548	CcSEcCtD
Atomoxetine—Myalgia—Dexamethasone—psoriasis	0.000226	0.000547	CcSEcCtD
Atomoxetine—Myalgia—Betamethasone—psoriasis	0.000226	0.000547	CcSEcCtD
Atomoxetine—Abdominal pain—Cyclosporine—psoriasis	0.000225	0.000546	CcSEcCtD
Atomoxetine—Body temperature increased—Cyclosporine—psoriasis	0.000225	0.000546	CcSEcCtD
Atomoxetine—Anxiety—Dexamethasone—psoriasis	0.000225	0.000545	CcSEcCtD
Atomoxetine—Anxiety—Betamethasone—psoriasis	0.000225	0.000545	CcSEcCtD
Atomoxetine—Vomiting—Mycophenolic acid—psoriasis	0.000224	0.000542	CcSEcCtD
Atomoxetine—Dyspepsia—Hydrocortisone—psoriasis	0.000223	0.00054	CcSEcCtD
Atomoxetine—Rash—Mycophenolic acid—psoriasis	0.000222	0.000538	CcSEcCtD
Atomoxetine—Dermatitis—Mycophenolic acid—psoriasis	0.000222	0.000537	CcSEcCtD
Atomoxetine—Pain—Prednisolone—psoriasis	0.000222	0.000537	CcSEcCtD
Atomoxetine—Urticaria—Mycophenolate mofetil—psoriasis	0.000221	0.000535	CcSEcCtD
Atomoxetine—Headache—Mycophenolic acid—psoriasis	0.000221	0.000534	CcSEcCtD
Atomoxetine—Decreased appetite—Hydrocortisone—psoriasis	0.00022	0.000533	CcSEcCtD
Atomoxetine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.00022	0.000532	CcSEcCtD
Atomoxetine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.00022	0.000532	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—psoriasis	0.000219	0.00053	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000219	0.000529	CcSEcCtD
Atomoxetine—Fatigue—Hydrocortisone—psoriasis	0.000219	0.000529	CcSEcCtD
Atomoxetine—Vision blurred—Prednisone—psoriasis	0.000218	0.000527	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—psoriasis	0.000217	0.000526	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000217	0.000526	CcSEcCtD
Atomoxetine—Pain—Hydrocortisone—psoriasis	0.000217	0.000524	CcSEcCtD
Atomoxetine—HTR6—GPCR ligand binding—HCAR2—psoriasis	0.000216	0.00697	CbGpPWpGaD
Atomoxetine—Insomnia—Triamcinolone—psoriasis	0.000216	0.000522	CcSEcCtD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000216	0.00696	CbGpPWpGaD
Atomoxetine—Infection—Betamethasone—psoriasis	0.000215	0.000521	CcSEcCtD
Atomoxetine—Infection—Dexamethasone—psoriasis	0.000215	0.000521	CcSEcCtD
Atomoxetine—Paraesthesia—Triamcinolone—psoriasis	0.000214	0.000519	CcSEcCtD
Atomoxetine—HTR1D—GPCR ligand binding—HCAR2—psoriasis	0.000214	0.00691	CbGpPWpGaD
Atomoxetine—Feeling abnormal—Prednisolone—psoriasis	0.000214	0.000517	CcSEcCtD
Atomoxetine—Shock—Dexamethasone—psoriasis	0.000213	0.000516	CcSEcCtD
Atomoxetine—Shock—Betamethasone—psoriasis	0.000213	0.000516	CcSEcCtD
Atomoxetine—Nervous system disorder—Betamethasone—psoriasis	0.000212	0.000514	CcSEcCtD
Atomoxetine—Nervous system disorder—Dexamethasone—psoriasis	0.000212	0.000514	CcSEcCtD
Atomoxetine—Agitation—Prednisone—psoriasis	0.000212	0.000514	CcSEcCtD
Atomoxetine—Tachycardia—Dexamethasone—psoriasis	0.000211	0.000511	CcSEcCtD
Atomoxetine—Tachycardia—Betamethasone—psoriasis	0.000211	0.000511	CcSEcCtD
Atomoxetine—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.000211	0.00679	CbGpPWpGaD
Atomoxetine—Dyspepsia—Triamcinolone—psoriasis	0.00021	0.000508	CcSEcCtD
Atomoxetine—HTR1B—GPCR ligand binding—HCAR2—psoriasis	0.00021	0.00677	CbGpPWpGaD
Atomoxetine—Nausea—Mycophenolic acid—psoriasis	0.000209	0.000507	CcSEcCtD
Atomoxetine—Hyperhidrosis—Dexamethasone—psoriasis	0.000209	0.000507	CcSEcCtD
Atomoxetine—Hyperhidrosis—Betamethasone—psoriasis	0.000209	0.000507	CcSEcCtD
Atomoxetine—Feeling abnormal—Hydrocortisone—psoriasis	0.000209	0.000505	CcSEcCtD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000209	0.00674	CbGpPWpGaD
Atomoxetine—Vertigo—Prednisone—psoriasis	0.000208	0.000502	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000207	0.000502	CcSEcCtD
Atomoxetine—Syncope—Prednisone—psoriasis	0.000207	0.000501	CcSEcCtD
Atomoxetine—Anorexia—Dexamethasone—psoriasis	0.000206	0.000499	CcSEcCtD
Atomoxetine—Anorexia—Betamethasone—psoriasis	0.000206	0.000499	CcSEcCtD
Atomoxetine—Urticaria—Prednisolone—psoriasis	0.000206	0.000499	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—psoriasis	0.000206	0.000498	CcSEcCtD
Atomoxetine—Fatigue—Triamcinolone—psoriasis	0.000206	0.000498	CcSEcCtD
Atomoxetine—Asthenia—Cyclosporine—psoriasis	0.000205	0.000495	CcSEcCtD
Atomoxetine—Pain—Triamcinolone—psoriasis	0.000204	0.000494	CcSEcCtD
Atomoxetine—Loss of consciousness—Prednisone—psoriasis	0.000203	0.000491	CcSEcCtD
Atomoxetine—Pruritus—Cyclosporine—psoriasis	0.000202	0.000488	CcSEcCtD
Atomoxetine—Urticaria—Hydrocortisone—psoriasis	0.000201	0.000487	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—psoriasis	0.000201	0.000487	CcSEcCtD
Atomoxetine—Body temperature increased—Hydrocortisone—psoriasis	0.0002	0.000485	CcSEcCtD
Atomoxetine—Abdominal pain—Hydrocortisone—psoriasis	0.0002	0.000485	CcSEcCtD
Atomoxetine—Convulsion—Prednisone—psoriasis	0.0002	0.000484	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—psoriasis	0.0002	0.000484	CcSEcCtD
Atomoxetine—Asthenia—Mycophenolate mofetil—psoriasis	0.0002	0.000483	CcSEcCtD
Atomoxetine—Chills—Methotrexate—psoriasis	0.000199	0.000482	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000197	0.000477	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000197	0.000477	CcSEcCtD
Atomoxetine—Pruritus—Mycophenolate mofetil—psoriasis	0.000197	0.000476	CcSEcCtD
Atomoxetine—Arthralgia—Prednisone—psoriasis	0.000197	0.000476	CcSEcCtD
Atomoxetine—Myalgia—Prednisone—psoriasis	0.000197	0.000476	CcSEcCtD
Atomoxetine—Feeling abnormal—Triamcinolone—psoriasis	0.000197	0.000476	CcSEcCtD
Atomoxetine—Anxiety—Prednisone—psoriasis	0.000196	0.000474	CcSEcCtD
Atomoxetine—Insomnia—Dexamethasone—psoriasis	0.000196	0.000474	CcSEcCtD
Atomoxetine—Insomnia—Betamethasone—psoriasis	0.000196	0.000474	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000195	0.000473	CcSEcCtD
Atomoxetine—Diarrhoea—Cyclosporine—psoriasis	0.000195	0.000472	CcSEcCtD
Atomoxetine—Paraesthesia—Betamethasone—psoriasis	0.000194	0.000471	CcSEcCtD
Atomoxetine—Paraesthesia—Dexamethasone—psoriasis	0.000194	0.000471	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—psoriasis	0.000194	0.00047	CcSEcCtD
Atomoxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000193	0.00623	CbGpPWpGaD
Atomoxetine—Malnutrition—Methotrexate—psoriasis	0.000193	0.000467	CcSEcCtD
Atomoxetine—Dyspepsia—Betamethasone—psoriasis	0.000191	0.000461	CcSEcCtD
Atomoxetine—Dyspepsia—Dexamethasone—psoriasis	0.000191	0.000461	CcSEcCtD
Atomoxetine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000191	0.00615	CbGpPWpGaD
Atomoxetine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00019	0.000461	CcSEcCtD
Atomoxetine—Urticaria—Triamcinolone—psoriasis	0.00019	0.000459	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—psoriasis	0.000189	0.000458	CcSEcCtD
Atomoxetine—Body temperature increased—Triamcinolone—psoriasis	0.000189	0.000457	CcSEcCtD
Atomoxetine—Dizziness—Cyclosporine—psoriasis	0.000189	0.000456	CcSEcCtD
Atomoxetine—Decreased appetite—Betamethasone—psoriasis	0.000188	0.000455	CcSEcCtD
Atomoxetine—Decreased appetite—Dexamethasone—psoriasis	0.000188	0.000455	CcSEcCtD
Atomoxetine—Infection—Prednisone—psoriasis	0.000187	0.000453	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000187	0.000452	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000187	0.000452	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—psoriasis	0.000187	0.000452	CcSEcCtD
Atomoxetine—Fatigue—Dexamethasone—psoriasis	0.000187	0.000452	CcSEcCtD
Atomoxetine—Fatigue—Betamethasone—psoriasis	0.000187	0.000452	CcSEcCtD
Atomoxetine—SLC6A3—NRF2 pathway—TGFA—psoriasis	0.000187	0.00602	CbGpPWpGaD
Atomoxetine—Shock—Prednisone—psoriasis	0.000186	0.000449	CcSEcCtD
Atomoxetine—Pain—Dexamethasone—psoriasis	0.000185	0.000448	CcSEcCtD
Atomoxetine—Pain—Betamethasone—psoriasis	0.000185	0.000448	CcSEcCtD
Atomoxetine—Nervous system disorder—Prednisone—psoriasis	0.000185	0.000448	CcSEcCtD
Atomoxetine—Tachycardia—Prednisone—psoriasis	0.000184	0.000445	CcSEcCtD
Atomoxetine—Dizziness—Mycophenolate mofetil—psoriasis	0.000184	0.000445	CcSEcCtD
Atomoxetine—HTR1D—G alpha (i) signalling events—CCL20—psoriasis	0.000184	0.00593	CbGpPWpGaD
Atomoxetine—Skin disorder—Prednisone—psoriasis	0.000183	0.000443	CcSEcCtD
Atomoxetine—SLC6A4—Monoamine Transport—TNF—psoriasis	0.000182	0.00588	CbGpPWpGaD
Atomoxetine—Hyperhidrosis—Prednisone—psoriasis	0.000182	0.000441	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—psoriasis	0.000182	0.00044	CcSEcCtD
Atomoxetine—Asthenia—Hydrocortisone—psoriasis	0.000182	0.00044	CcSEcCtD
Atomoxetine—Vomiting—Cyclosporine—psoriasis	0.000181	0.000439	CcSEcCtD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000181	0.00585	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—CCL20—psoriasis	0.00018	0.00581	CbGpPWpGaD
Atomoxetine—Rash—Cyclosporine—psoriasis	0.00018	0.000435	CcSEcCtD
Atomoxetine—Anorexia—Prednisone—psoriasis	0.00018	0.000435	CcSEcCtD
Atomoxetine—Dermatitis—Cyclosporine—psoriasis	0.00018	0.000435	CcSEcCtD
Atomoxetine—Pruritus—Hydrocortisone—psoriasis	0.000179	0.000434	CcSEcCtD
Atomoxetine—Headache—Cyclosporine—psoriasis	0.000179	0.000432	CcSEcCtD
Atomoxetine—Feeling abnormal—Dexamethasone—psoriasis	0.000178	0.000432	CcSEcCtD
Atomoxetine—Feeling abnormal—Betamethasone—psoriasis	0.000178	0.000432	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—HCAR2—psoriasis	0.000177	0.00573	CbGpPWpGaD
Atomoxetine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000177	0.000428	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Betamethasone—psoriasis	0.000177	0.000428	CcSEcCtD
Atomoxetine—Vomiting—Mycophenolate mofetil—psoriasis	0.000177	0.000428	CcSEcCtD
Atomoxetine—Rash—Mycophenolate mofetil—psoriasis	0.000175	0.000424	CcSEcCtD
Atomoxetine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000175	0.000424	CcSEcCtD
Atomoxetine—Headache—Mycophenolate mofetil—psoriasis	0.000174	0.000422	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—psoriasis	0.000174	0.00042	CcSEcCtD
Atomoxetine—Diarrhoea—Hydrocortisone—psoriasis	0.000173	0.00042	CcSEcCtD
Atomoxetine—Urticaria—Dexamethasone—psoriasis	0.000172	0.000416	CcSEcCtD
Atomoxetine—Urticaria—Betamethasone—psoriasis	0.000172	0.000416	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Prednisone—psoriasis	0.000172	0.000416	CcSEcCtD
Atomoxetine—NPY1R—GPCR downstream signaling—CCL20—psoriasis	0.000172	0.00554	CbGpPWpGaD
Atomoxetine—Dizziness—Prednisolone—psoriasis	0.000172	0.000415	CcSEcCtD
Atomoxetine—Asthenia—Triamcinolone—psoriasis	0.000171	0.000414	CcSEcCtD
Atomoxetine—Abdominal pain—Betamethasone—psoriasis	0.000171	0.000414	CcSEcCtD
Atomoxetine—Abdominal pain—Dexamethasone—psoriasis	0.000171	0.000414	CcSEcCtD
Atomoxetine—Body temperature increased—Dexamethasone—psoriasis	0.000171	0.000414	CcSEcCtD
Atomoxetine—Body temperature increased—Betamethasone—psoriasis	0.000171	0.000414	CcSEcCtD
Atomoxetine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000171	0.00551	CbGpPWpGaD
Atomoxetine—Insomnia—Prednisone—psoriasis	0.000171	0.000413	CcSEcCtD
Atomoxetine—Nausea—Cyclosporine—psoriasis	0.000169	0.00041	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisone—psoriasis	0.000169	0.00041	CcSEcCtD
Atomoxetine—SLC6A3—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000169	0.00545	CbGpPWpGaD
Atomoxetine—Pruritus—Triamcinolone—psoriasis	0.000169	0.000409	CcSEcCtD
Atomoxetine—Cough—Methotrexate—psoriasis	0.000169	0.000408	CcSEcCtD
Atomoxetine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000168	0.00543	CbGpPWpGaD
Atomoxetine—Dizziness—Hydrocortisone—psoriasis	0.000168	0.000406	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—psoriasis	0.000167	0.000405	CcSEcCtD
Atomoxetine—Dyspepsia—Prednisone—psoriasis	0.000166	0.000402	CcSEcCtD
Atomoxetine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000165	0.00534	CbGpPWpGaD
Atomoxetine—Nausea—Mycophenolate mofetil—psoriasis	0.000165	0.0004	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—psoriasis	0.000164	0.000398	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—psoriasis	0.000164	0.000398	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—psoriasis	0.000164	0.000398	CcSEcCtD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000164	0.0053	CbGpPWpGaD
Atomoxetine—Decreased appetite—Prednisone—psoriasis	0.000164	0.000397	CcSEcCtD
Atomoxetine—Rash—Prednisolone—psoriasis	0.000164	0.000396	CcSEcCtD
Atomoxetine—Dermatitis—Prednisolone—psoriasis	0.000163	0.000396	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000163	0.000395	CcSEcCtD
Atomoxetine—Fatigue—Prednisone—psoriasis	0.000163	0.000393	CcSEcCtD
Atomoxetine—Headache—Prednisolone—psoriasis	0.000163	0.000393	CcSEcCtD
Atomoxetine—Constipation—Prednisone—psoriasis	0.000161	0.00039	CcSEcCtD
Atomoxetine—Vomiting—Hydrocortisone—psoriasis	0.000161	0.00039	CcSEcCtD
Atomoxetine—NPY1R—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000161	0.00519	CbGpPWpGaD
Atomoxetine—Rash—Hydrocortisone—psoriasis	0.00016	0.000387	CcSEcCtD
Atomoxetine—Dermatitis—Hydrocortisone—psoriasis	0.00016	0.000386	CcSEcCtD
Atomoxetine—HTR2C—GPCR ligand binding—HCAR2—psoriasis	0.000159	0.00513	CbGpPWpGaD
Atomoxetine—Headache—Hydrocortisone—psoriasis	0.000159	0.000384	CcSEcCtD
Atomoxetine—Dizziness—Triamcinolone—psoriasis	0.000158	0.000382	CcSEcCtD
Atomoxetine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000157	0.00506	CbGpPWpGaD
Atomoxetine—SLC6A2—Monoamine Transport—TNF—psoriasis	0.000157	0.00506	CbGpPWpGaD
Atomoxetine—Infection—Methotrexate—psoriasis	0.000157	0.000379	CcSEcCtD
Atomoxetine—NPY1R—Signaling by GPCR—CCL20—psoriasis	0.000156	0.00503	CbGpPWpGaD
Atomoxetine—Feeling abnormal—Prednisone—psoriasis	0.000155	0.000376	CcSEcCtD
Atomoxetine—Asthenia—Dexamethasone—psoriasis	0.000155	0.000376	CcSEcCtD
Atomoxetine—Asthenia—Betamethasone—psoriasis	0.000155	0.000376	CcSEcCtD
Atomoxetine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000155	0.00499	CbGpPWpGaD
Atomoxetine—Nervous system disorder—Methotrexate—psoriasis	0.000155	0.000374	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Prednisone—psoriasis	0.000154	0.000373	CcSEcCtD
Atomoxetine—Nausea—Prednisolone—psoriasis	0.000154	0.000373	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—TAGAP—psoriasis	0.000154	0.00496	CbGpPWpGaD
Atomoxetine—Pruritus—Dexamethasone—psoriasis	0.000153	0.000371	CcSEcCtD
Atomoxetine—Pruritus—Betamethasone—psoriasis	0.000153	0.000371	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—psoriasis	0.000153	0.00037	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—psoriasis	0.000152	0.000369	CcSEcCtD
Atomoxetine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000152	0.00491	CbGpPWpGaD
Atomoxetine—Vomiting—Triamcinolone—psoriasis	0.000152	0.000367	CcSEcCtD
Atomoxetine—Nausea—Hydrocortisone—psoriasis	0.000151	0.000364	CcSEcCtD
Atomoxetine—Rash—Triamcinolone—psoriasis	0.00015	0.000364	CcSEcCtD
Atomoxetine—Dermatitis—Triamcinolone—psoriasis	0.00015	0.000364	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—psoriasis	0.00015	0.000364	CcSEcCtD
Atomoxetine—Urticaria—Prednisone—psoriasis	0.00015	0.000363	CcSEcCtD
Atomoxetine—Headache—Triamcinolone—psoriasis	0.00015	0.000362	CcSEcCtD
Atomoxetine—Abdominal pain—Prednisone—psoriasis	0.000149	0.000361	CcSEcCtD
Atomoxetine—Body temperature increased—Prednisone—psoriasis	0.000149	0.000361	CcSEcCtD
Atomoxetine—Diarrhoea—Betamethasone—psoriasis	0.000148	0.000359	CcSEcCtD
Atomoxetine—Diarrhoea—Dexamethasone—psoriasis	0.000148	0.000359	CcSEcCtD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000147	0.00475	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000146	0.00472	CbGpPWpGaD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000144	0.000347	CcSEcCtD
Atomoxetine—Dizziness—Dexamethasone—psoriasis	0.000143	0.000346	CcSEcCtD
Atomoxetine—Dizziness—Betamethasone—psoriasis	0.000143	0.000346	CcSEcCtD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000143	0.00462	CbGpPWpGaD
Atomoxetine—Insomnia—Methotrexate—psoriasis	0.000143	0.000345	CcSEcCtD
Atomoxetine—Nausea—Triamcinolone—psoriasis	0.000142	0.000343	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—psoriasis	0.000142	0.000342	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—psoriasis	0.00014	0.000339	CcSEcCtD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000139	0.00449	CbGpPWpGaD
Atomoxetine—SLC6A3—Monoamine Transport—TNF—psoriasis	0.000139	0.00448	CbGpPWpGaD
Atomoxetine—Dyspepsia—Methotrexate—psoriasis	0.000139	0.000336	CcSEcCtD
Atomoxetine—HTR2A—GPCR ligand binding—HCAR2—psoriasis	0.000138	0.00446	CbGpPWpGaD
Atomoxetine—Vomiting—Betamethasone—psoriasis	0.000138	0.000333	CcSEcCtD
Atomoxetine—Vomiting—Dexamethasone—psoriasis	0.000138	0.000333	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—psoriasis	0.000137	0.000332	CcSEcCtD
Atomoxetine—Rash—Betamethasone—psoriasis	0.000137	0.00033	CcSEcCtD
Atomoxetine—Rash—Dexamethasone—psoriasis	0.000137	0.00033	CcSEcCtD
Atomoxetine—Dermatitis—Betamethasone—psoriasis	0.000136	0.00033	CcSEcCtD
Atomoxetine—Dermatitis—Dexamethasone—psoriasis	0.000136	0.00033	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000136	0.000329	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—psoriasis	0.000136	0.000329	CcSEcCtD
Atomoxetine—Headache—Betamethasone—psoriasis	0.000136	0.000328	CcSEcCtD
Atomoxetine—Headache—Dexamethasone—psoriasis	0.000136	0.000328	CcSEcCtD
Atomoxetine—NPY1R—G alpha (i) signalling events—CXCL8—psoriasis	0.000136	0.00438	CbGpPWpGaD
Atomoxetine—Asthenia—Prednisone—psoriasis	0.000135	0.000327	CcSEcCtD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000135	0.00435	CbGpPWpGaD
Atomoxetine—Pain—Methotrexate—psoriasis	0.000135	0.000326	CcSEcCtD
Atomoxetine—Pruritus—Prednisone—psoriasis	0.000133	0.000323	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—psoriasis	0.00013	0.000314	CcSEcCtD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL13—psoriasis	0.00013	0.00419	CbGpPWpGaD
Atomoxetine—Diarrhoea—Prednisone—psoriasis	0.000129	0.000312	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—psoriasis	0.000129	0.000312	CcSEcCtD
Atomoxetine—Nausea—Dexamethasone—psoriasis	0.000129	0.000311	CcSEcCtD
Atomoxetine—Nausea—Betamethasone—psoriasis	0.000129	0.000311	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—psoriasis	0.000125	0.000303	CcSEcCtD
Atomoxetine—Dizziness—Prednisone—psoriasis	0.000125	0.000302	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—psoriasis	0.000125	0.000301	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—psoriasis	0.000125	0.000301	CcSEcCtD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000123	0.00398	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HCAR2—psoriasis	0.000122	0.00394	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HCAR2—psoriasis	0.000121	0.00391	CbGpPWpGaD
Atomoxetine—Vomiting—Prednisone—psoriasis	0.00012	0.00029	CcSEcCtD
Atomoxetine—Rash—Prednisone—psoriasis	0.000119	0.000288	CcSEcCtD
Atomoxetine—Dermatitis—Prednisone—psoriasis	0.000119	0.000287	CcSEcCtD
Atomoxetine—HTR1B—GPCR downstream signaling—HCAR2—psoriasis	0.000119	0.00383	CbGpPWpGaD
Atomoxetine—Headache—Prednisone—psoriasis	0.000118	0.000286	CcSEcCtD
Atomoxetine—Asthenia—Methotrexate—psoriasis	0.000113	0.000274	CcSEcCtD
Atomoxetine—HTR6—GPCR ligand binding—CCL20—psoriasis	0.000112	0.00362	CbGpPWpGaD
Atomoxetine—Nausea—Prednisone—psoriasis	0.000112	0.000271	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—psoriasis	0.000112	0.00027	CcSEcCtD
Atomoxetine—HTR1D—GPCR ligand binding—CCL20—psoriasis	0.000111	0.00359	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HCAR2—psoriasis	0.000111	0.00358	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HCAR2—psoriasis	0.00011	0.00355	CbGpPWpGaD
Atomoxetine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000109	0.00353	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CCL20—psoriasis	0.000109	0.00352	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000108	0.0035	CbGpPWpGaD
Atomoxetine—Diarrhoea—Methotrexate—psoriasis	0.000108	0.000261	CcSEcCtD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000108	0.00348	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HCAR2—psoriasis	0.000108	0.00347	CbGpPWpGaD
Atomoxetine—Dizziness—Methotrexate—psoriasis	0.000104	0.000252	CcSEcCtD
Atomoxetine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000103	0.00331	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000101	0.00327	CbGpPWpGaD
Atomoxetine—Vomiting—Methotrexate—psoriasis	0.0001	0.000242	CcSEcCtD
Atomoxetine—Rash—Methotrexate—psoriasis	9.94e-05	0.00024	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—psoriasis	9.93e-05	0.00024	CcSEcCtD
Atomoxetine—Headache—Methotrexate—psoriasis	9.87e-05	0.000239	CcSEcCtD
Atomoxetine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	9.84e-05	0.00317	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.42e-05	0.00304	CbGpPWpGaD
Atomoxetine—Nausea—Methotrexate—psoriasis	9.36e-05	0.000227	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—CCL20—psoriasis	9.22e-05	0.00297	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	9.06e-05	0.00292	CbGpPWpGaD
Atomoxetine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	9.05e-05	0.00292	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	8.99e-05	0.0029	CbGpPWpGaD
Atomoxetine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.85e-05	0.00286	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	8.44e-05	0.00272	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CCL20—psoriasis	8.26e-05	0.00266	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—CXCL8—psoriasis	8.21e-05	0.00265	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HCAR2—psoriasis	8.16e-05	0.00263	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL10—psoriasis	8.12e-05	0.00262	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	7.89e-05	0.00255	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—HCAR2—psoriasis	7.8e-05	0.00252	CbGpPWpGaD
Atomoxetine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.63e-05	0.00246	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.38e-05	0.00238	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCL20—psoriasis	7.17e-05	0.00231	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HCAR2—psoriasis	7.09e-05	0.00229	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	7.07e-05	0.00228	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	6.86e-05	0.00221	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	6.74e-05	0.00218	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.6e-05	0.00213	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HCAR2—psoriasis	6.55e-05	0.00211	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HCAR2—psoriasis	6.5e-05	0.0021	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HCAR2—psoriasis	6.36e-05	0.00205	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CCL20—psoriasis	6.34e-05	0.00205	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CCL20—psoriasis	6.29e-05	0.00203	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	6.26e-05	0.00202	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CCL20—psoriasis	6.16e-05	0.00199	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.99e-05	0.00193	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	5.97e-05	0.00193	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCL20—psoriasis	5.76e-05	0.00186	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCL20—psoriasis	5.71e-05	0.00184	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TAGAP—psoriasis	5.68e-05	0.00183	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TAGAP—psoriasis	5.63e-05	0.00182	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	5.6e-05	0.00181	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCL20—psoriasis	5.59e-05	0.0018	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TAGAP—psoriasis	5.51e-05	0.00178	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	5.13e-05	0.00166	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SOCS1—psoriasis	5.08e-05	0.00164	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—CXCL8—psoriasis	4.96e-05	0.0016	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—CXCL8—psoriasis	4.86e-05	0.00157	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—TYK2—psoriasis	4.84e-05	0.00156	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HCAR2—psoriasis	4.82e-05	0.00156	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CCL20—psoriasis	4.67e-05	0.00151	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—CXCL8—psoriasis	4.64e-05	0.0015	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.54e-05	0.00147	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.44e-05	0.00143	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL20—psoriasis	4.24e-05	0.00137	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CXCL8—psoriasis	4.21e-05	0.00136	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HCAR2—psoriasis	4.19e-05	0.00135	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TAGAP—psoriasis	4.18e-05	0.00135	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	4.14e-05	0.00134	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—JUN—psoriasis	4.13e-05	0.00133	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CCL20—psoriasis	4.05e-05	0.00131	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.98e-05	0.00128	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.97e-05	0.00128	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.95e-05	0.00127	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.94e-05	0.00127	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.86e-05	0.00125	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—LEP—psoriasis	3.75e-05	0.00121	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—APOE—psoriasis	3.75e-05	0.00121	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	3.7e-05	0.00119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL20—psoriasis	3.68e-05	0.00119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TAGAP—psoriasis	3.63e-05	0.00117	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.61e-05	0.00116	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NFKBIA—psoriasis	3.49e-05	0.00113	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NDUFA5—psoriasis	3.43e-05	0.00111	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL20—psoriasis	3.4e-05	0.0011	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	3.38e-05	0.00109	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL20—psoriasis	3.37e-05	0.00109	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL20—psoriasis	3.3e-05	0.00107	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.2e-05	0.00103	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NDUFA5—psoriasis	3.16e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	3.09e-05	0.000997	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CXCL8—psoriasis	3.03e-05	0.000977	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CXCL8—psoriasis	3.01e-05	0.00097	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CXCL8—psoriasis	2.94e-05	0.00095	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.93e-05	0.000945	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.92e-05	0.000942	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TYK2—psoriasis	2.86e-05	0.000922	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.68e-05	0.000866	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.54e-05	0.000821	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL20—psoriasis	2.5e-05	0.000808	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	2.49e-05	0.000805	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CXCL8—psoriasis	2.49e-05	0.000803	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL6—psoriasis	2.37e-05	0.000764	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—JUN—psoriasis	2.31e-05	0.000747	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CXCL8—psoriasis	2.23e-05	0.00072	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NFKB1—psoriasis	2.23e-05	0.000719	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.22e-05	0.000717	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL20—psoriasis	2.17e-05	0.000702	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NDUFA5—psoriasis	2.06e-05	0.000666	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VEGFA—psoriasis	2.02e-05	0.000652	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—STAT3—psoriasis	2e-05	0.000646	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CXCL8—psoriasis	1.94e-05	0.000625	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.93e-05	0.000623	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SOCS1—psoriasis	1.87e-05	0.000604	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SOCS1—psoriasis	1.86e-05	0.0006	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SOCS1—psoriasis	1.82e-05	0.000587	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TYK2—psoriasis	1.78e-05	0.000576	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TYK2—psoriasis	1.77e-05	0.000572	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.75e-05	0.000566	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TYK2—psoriasis	1.73e-05	0.00056	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CXCL8—psoriasis	1.71e-05	0.000552	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CXCL8—psoriasis	1.7e-05	0.000548	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CXCL8—psoriasis	1.66e-05	0.000537	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CXCL8—psoriasis	1.55e-05	0.000502	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CXCL8—psoriasis	1.54e-05	0.000498	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.53e-05	0.000493	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—psoriasis	1.53e-05	0.000493	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CXCL8—psoriasis	1.51e-05	0.000487	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CARM1—psoriasis	1.42e-05	0.00046	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—psoriasis	1.4e-05	0.000451	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LEP—psoriasis	1.38e-05	0.000446	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—psoriasis	1.38e-05	0.000446	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SOCS1—psoriasis	1.38e-05	0.000445	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LEP—psoriasis	1.37e-05	0.000442	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—psoriasis	1.37e-05	0.000442	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—psoriasis	1.34e-05	0.000433	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LEP—psoriasis	1.34e-05	0.000433	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.33e-05	0.00043	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TYK2—psoriasis	1.31e-05	0.000424	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CARM1—psoriasis	1.31e-05	0.000423	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NFKBIA—psoriasis	1.29e-05	0.000415	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NFKBIA—psoriasis	1.28e-05	0.000412	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	1.26e-05	0.000407	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NFKBIA—psoriasis	1.25e-05	0.000404	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SOCS1—psoriasis	1.2e-05	0.000386	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL8—psoriasis	1.14e-05	0.000369	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TYK2—psoriasis	1.14e-05	0.000368	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	1.09e-05	0.000353	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TYK2—psoriasis	1.05e-05	0.00034	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TYK2—psoriasis	1.05e-05	0.000338	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TYK2—psoriasis	1.02e-05	0.000331	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—psoriasis	1.02e-05	0.000328	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LEP—psoriasis	1.02e-05	0.000328	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL8—psoriasis	9.94e-06	0.000321	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	9.48e-06	0.000306	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL8—psoriasis	9.18e-06	0.000296	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL8—psoriasis	9.11e-06	0.000294	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—psoriasis	8.92e-06	0.000288	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—psoriasis	8.83e-06	0.000285	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—psoriasis	8.83e-06	0.000285	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAT—psoriasis	8.76e-06	0.000283	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—psoriasis	8.73e-06	0.000282	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—psoriasis	8.66e-06	0.00028	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CARM1—psoriasis	8.57e-06	0.000277	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—JUN—psoriasis	8.54e-06	0.000275	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—psoriasis	8.48e-06	0.000274	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—JUN—psoriasis	8.47e-06	0.000273	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JUN—psoriasis	8.29e-06	0.000268	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NFKBIA—psoriasis	8.23e-06	0.000266	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NFKB1—psoriasis	8.22e-06	0.000265	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NFKB1—psoriasis	8.15e-06	0.000263	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAT—psoriasis	8.06e-06	0.00026	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NFKB1—psoriasis	7.98e-06	0.000258	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TYK2—psoriasis	7.77e-06	0.000251	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—psoriasis	7.46e-06	0.000241	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—psoriasis	7.4e-06	0.000239	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—psoriasis	7.38e-06	0.000238	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—psoriasis	7.33e-06	0.000236	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—psoriasis	7.25e-06	0.000234	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—psoriasis	7.17e-06	0.000232	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—psoriasis	6.81e-06	0.00022	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—psoriasis	6.76e-06	0.000218	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TYK2—psoriasis	6.74e-06	0.000218	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—psoriasis	6.43e-06	0.000207	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUN—psoriasis	6.29e-06	0.000203	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—psoriasis	6.26e-06	0.000202	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NFKB1—psoriasis	6.05e-06	0.000195	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—psoriasis	5.93e-06	0.000191	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—psoriasis	5.87e-06	0.000189	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—psoriasis	5.63e-06	0.000182	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—psoriasis	5.59e-06	0.00018	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—psoriasis	5.58e-06	0.00018	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—psoriasis	5.49e-06	0.000177	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—psoriasis	5.47e-06	0.000177	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUN—psoriasis	5.46e-06	0.000176	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—psoriasis	5.46e-06	0.000176	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—psoriasis	5.44e-06	0.000175	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAT—psoriasis	5.27e-06	0.00017	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NFKB1—psoriasis	5.25e-06	0.00017	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—psoriasis	5.16e-06	0.000166	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—psoriasis	5.12e-06	0.000165	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—psoriasis	5.01e-06	0.000162	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—psoriasis	4.77e-06	0.000154	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—psoriasis	4.72e-06	0.000152	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—psoriasis	4.15e-06	0.000134	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—psoriasis	4.1e-06	0.000132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—psoriasis	3.8e-06	0.000123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—psoriasis	3.6e-06	0.000116	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—psoriasis	3.57e-06	0.000115	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—psoriasis	3.3e-06	0.000106	CbGpPWpGaD
